Page last updated: 2024-09-05

deferasirox and hydrazine

deferasirox has been researched along with hydrazine in 4 studies

Compound Research Comparison

Studies
(deferasirox)
Trials
(deferasirox)
Recent Studies (post-2010)
(deferasirox)
Studies
(hydrazine)
Trials
(hydrazine)
Recent Studies (post-2010) (hydrazine)
83213657212,0343303,193

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (25.00)24.3611
2020's3 (75.00)2.80

Authors

AuthorsStudies
Argenziano, M; Casale, M; Perrotta, S; Punzo, F; Rossi, F; Tortora, C1
Andreani, G; Cilloni, D; De Gobbi, M; Dragani, M; Saglio, G1
Argenziano, M; Di Martino, M; Di Paola, A; Di Pinto, D; Perrotta, S; Pota, E; Punzo, F; Rossi, F; Tortora, C1
Fu, R; Huang, L; Liu, C; Liu, Z; Tian, M1

Reviews

1 review(s) available for deferasirox and hydrazine

ArticleYear
Synergistic effect of eltrombopag and deferasirox in aplastic anemia: a clinical case and review of the literature.
    Leukemia & lymphoma, 2020, Volume: 61, Issue:1

    Topics: Anemia, Aplastic; Benzoates; Deferasirox; Humans; Hydrazines; Pyrazoles

2020

Other Studies

3 other study(ies) available for deferasirox and hydrazine

ArticleYear
Iron chelating properties of Eltrombopag: Investigating its role in thalassemia-induced osteoporosis.
    PloS one, 2018, Volume: 13, Issue:12

    Topics: Adult; Benzoates; Blood Transfusion; Bone and Bones; Cell Differentiation; Deferasirox; Drug Evaluation; Female; Ferritins; Healthy Volunteers; Humans; Hydrazines; Iron; Iron Chelating Agents; Iron Overload; Leukocytes, Mononuclear; Osteoclasts; Osteoporosis; Primary Cell Culture; Pyrazoles; Receptors, Thrombopoietin; Thalassemia; Transfusion Reaction

2018
Effects of Iron Chelation in Osteosarcoma.
    Current cancer drug targets, 2021, Volume: 21, Issue:5

    Topics: Apoptosis; Benzoates; Bone Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deferasirox; Drug Therapy, Combination; Humans; Hydrazines; Iron Chelating Agents; Osteosarcoma; Pyrazoles; Treatment Outcome

2021
Deferasirox combination with eltrombopag shows anti-myelodysplastic syndrome effects by enhancing iron deprivation-related apoptosis.
    Journal of investigative medicine : the official publication of the American Federation for Clinical Research, 2022, Volume: 70, Issue:4

    Topics: Apoptosis; Benzoates; Deferasirox; Humans; Hydrazines; Iron; Iron Chelating Agents; Myelodysplastic Syndromes; Pyrazoles; Thrombocytopenia

2022